|
Jul 23
|
Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?
|
|
Jun 25
|
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
|
|
May 10
|
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
|
|
May 9
|
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
May 3
|
With 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional owners
|
|
Apr 9
|
3 Biotech Stocks to Dump Before They Go to Zero
|
|
Apr 4
|
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
|
|
Mar 16
|
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
|
|
Mar 14
|
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Feb 26
|
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
|
|
Jan 18
|
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
|
|
Jan 18
|
Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks
|
|
Jan 17
|
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
|
|
Jan 16
|
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
|
|
Jan 16
|
UPDATE 2-Allakos tumbles after skin disease drug fails mid-stage studies
|
|
Jan 16
|
Allakos Announces a Restructuring to Focus on Development of AK006
|
|
Jan 16
|
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
|
|
Jan 16
|
Allakos to lay off half of staff, scrap drug after study setback
|
|
Jan 9
|
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
|
|
Nov 13
|
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023
|